Effectiveness of Bortezomib in Cardiac AL Amyloidosis: A Report of Two Cases

Table 1

Followup of case report 1.

	June 2006; Basal	March 2007; after mel/dex	January 2008; after bort/dex	April; 2008	October; 2008	April; 2009	September; 2009	September; 2013
Serum free 𝑘 light chains; mg/dL (n.v. < 19.4 )	292	110	10.6	12.07	12.03	12.09	13.05	7
𝑘/𝜆 ratio; (0.26–1.65)	56.1	32.16	1.1	1.01	1.00	2.01	0.94
NTproBNP ng/mL; (n.v. < 227)	5570	8593	840	695	521	482	423	204
Troponin I ng/mL; (n.v. < 0.06)	0.85	3.23	0.59	0.83	0.85	0.19	0.19	0.05
IVS (mm)	16	16	14	14	12	12	12	11
LVPW (mm)	16	15	14	14	12	12	12	11

mel: melphalan; dex: dexamethasone; bort: bortezomib.